Diethylenetriaminepentaacetic acid

393.35

393.35

1810219

200-652-8

7A314HQM0I

759314|7340

DTXSID2023434

C460

2916190090

196

-8.5

White to almost white Crystalline Powder

1.56

219-220 °C(lit.)

Decomposes

200 °C

1.590

H2O: 5 g/L (20 ºC);0.1 M NaOH: 0.1 M at 20 °C, clear, colorless

-20°C

LD50 orally in Rabbit: > 2000 mg/kg

pentabasic (1.5-10.6)

pentabasic (1.5-10.6)

180.2 Ų [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

9

UN 3077 9/PG 3

2

36-51/53-36/37/38-20-63

26-36-61-37/39-36/37

MB8205000

Xi,N,Xn

Stable. Incompatible with strong oxidizing agents.

P281-P305 + P351 + P338

H319-H332-H361d

|Warning|H319 (99.77%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]|P201, P202, P260, P261, P264, P271, P280, P281, P304+P312, P304+P340, P305+P351+P338, P308+P313, P312, P314, P337+P313, P405, and P501|Aggregated GHS information provided by 503 companies from 29 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Some toxicity has been reported related to administration of pentetic acid including depletion of trace metals, kidney and liver vacuolization and small bowel hemorrhage lesions.

The fast clearance and very short half-life of pentetic acid suggest that this compound is very unlikely to become bound to serum proteins to any significant extent. It is reported that DPTA is negligibly bound to alpha1-antitrypsin.

DTPA is widely used in industry and medicine. As a medical agent, it is approved for its use in medical imaging and for the decorporation of internally deposited radionuclides. It is FDA approved for the treatment of individuals with known or suspected internal contamination with plutonium, americium or curium to increase the rates of elimination. Due to the pharmacokinetic elimination by the kidneys, pentetic acid conjugated with technetium Tc-99m is being used clinically to estimate physiological parameters such as glomerular filtration rat and effective renal plasma flow.|FDA Label

There are reports in vivo of low stability of complexes of DPTA with uranium and neptunium which is being reported to cause deposition of the radionuclides into the tissues. In the case of plutonium, some preclinical studies have shown a very high urine elimination efficacy 1 hour after initial contamination. This efficacy is conserved for approximately 24 hours while the radiocontaminant is circulating. When the radionuclide is inhaled, it has been reported a DPTA-induced reduction of even 98% of the lung deposits. It is important to consider that pentetic acid can bind directly to other trace metals in the body which can cause deficiencies.

Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)|Organic chemicals that form two or more coordination links with an iron ion. Once coordination has occurred, the complex formed is called a chelate. The iron-binding porphyrin group of hemoglobin is an example of a metal chelate found in biological systems. (See all compounds classified as Iron Chelating Agents.)|Agents counteracting or neutralizing the action of POISONS. (See all compounds classified as Antidotes.)

DTPA and its trisodium salts present a very poor bioavailability after oral administration. Therefore, the normal administration of DTPA is done by slow intravenous infusion or inhalation with a nebulizer. When inhaled, the absorption is of about 20% of the administered dose.|DTPA metal complexes are quickly excreted in the urine.It is predominantly excreted by the kidney and it is not excreted by non-renal routes to any significant extent.|The volume of distribution of DPTA is 17 L.|Pentetic acid presents a very rapid blood clearance which explains for the short half-life. The reported clearance rate in patients with normal renal function is 80-120ml/min.

Pentetic acid and its derivatives present a very minimal metabolism in the body.

In preclinical studies, DTPA has been shown to present a very short half-life of 18.5-31.8 min after intravenous administration.

The calcium and zinc trisodium salts of DTPA achieve the therapeutical potential by exchanging calcium and zinc cations with transuranic radionuclides to form higher affinity complexes and then promote their elimination by glomerular filtration into the urine. DTPA as an acid acts in a very similar way by sequestering ions with its eight coordinate bond forming sites.

Ca-DTPA

All other basic organic chemical manufacturing|Glycine, N,N-bis[2-[bis(carboxymethyl)amino]ethyl]-: ACTIVE

Cosmetics -> Chelating